+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma

Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma

Clinical Lung Cancer 17(2): E5-11

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057940148

Download citation: RISBibTeXText

PMID: 26700910

DOI: 10.1016/j.cllc.2015.11.003

Related references

Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients. Oncology Reports 32(1): 145-152, 2015

A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. Journal of the National Comprehensive Cancer Network 12(1): 6-11; Quiz 11, 2014

The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M. Oncotarget 7(30): 48059-48069, 2016

Case report of three EGFR TKI naïve lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology. Pathology, Research and Practice: -, 2018

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma. Oncotarget 8(3): 4994-5002, 2016

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. Bmc Cancer 18(1): 1241-1241, 2018

Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors. Thoracic Cancer: -, 2018

Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M. Journal of Thoracic Oncology 13(8): E140-E142, 2018

MA 15.08 Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation. Journal of Thoracic Oncology 12(11): S1863-S1864, 2017

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clinical Cancer Research 17(5): 1160-1168, 2011

Screening for germline EGFR T790M mutations through lung cancer genotyping. Journal of Thoracic Oncology 7(6): 1049-1052, 2012

Germline EGFR T790M mutation found in multiple members of a familial cohort. Journal of Thoracic Oncology 9(4): 554-558, 2015

Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report. Thoracic Cancer: -, 2018

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. International Journal of Cancer 2018: -, 2018

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discovery 4(9): 1036-1045, 2016